Y-mAbs Therapeutics Interest Expense 2011-2026 | YMAB

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Y-mAbs Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-757 K	-1.85 M	598 K	1.98 M	-44 K	83 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.98 M	-1.85 M	667

Quarterly Interest Expense Y-mAbs Therapeutics

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	1.11 M	-	-1.51 M	-1.19 M	-373 K	-	-154 K	-225 K	-338 K	-	-191 K	59 K	568 K	-	437 K	598 K	319 K	-	-11 K	-47 K	-4 K	-	15 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.11 M	-1.51 M	-54.8 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Coherus BioSciences CHRS	9 M	$ 1.57	-3.68 %	$ 184 M	USA
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
Amphastar Pharmaceuticals AMPH	23 K	$ 16.87	-2.49 %	$ 789 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 7.47	-4.6 %	$ 205 M	Israel
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 30.26	1.0 %	$ 814 M	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Exelixis EXEL	-198 K	$ 50.13	-1.9 %	$ 13.6 B	USA
Fortress Biotech FBIO	17.6 M	$ 2.41	4.78 %	$ 67.2 M	USA
Forte Biosciences FBRX	-396 K	$ 23.11	-3.55 %	$ 299 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 4.09	-7.05 %	$ 1.22 B	Canada
Autolus Therapeutics plc AUTL	36.7 M	$ 1.63	2.52 %	$ 434 M	Britain
BioNTech SE BNTX	14.2 M	$ 89.55	-2.65 %	$ 21.6 B	Germany
Galectin Therapeutics GALT	1.03 M	$ 2.17	-7.66 %	$ 139 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Gilead Sciences GILD	-1 M	$ 129.58	-1.88 %	$ 161 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.36	-3.72 %	$ 5.53 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.72	-1.58 %	$ 32.9 M	Israel
Esperion Therapeutics ESPR	3.49 M	$ 3.12	-	$ 649 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	-43 K	-	-	$ 28.6 M	USA